PHASE I STUDY OF ADOPTIVE T CELL THERAPY FOLLOWING HER2-PULSED DENDRITIC CELL VACCINE AND PEPINEMAB/TRASTUZUMAB IN PATIENTS WITH METASTATIC HER2-POSITIVE BREAST CANCER (MBC)

被引：0
|
作者：
Han, Hyo [1 ]
Evans, Elizabeth [2 ]
Fisher, Terrence [2 ]
Soliman, Hatem [1 ]
Khong, Hung [1 ]
Soyano, Aixa [1 ]
Costa, Ricardo [1 ]
Loftus, Loretta [1 ]
Lee, Kimberley [1 ]
Armaghani, Avan [1 ]
Liu, Hien [1 ]
Locke, Frederick [1 ]
Shrewsbury, Alexandria [1 ]
Malka, Jessica [1 ]
Karyampudi, Lavakumar [1 ]
Zauderer, Maurice [2 ]
Czerniecki, Brian [1 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[2] Vaccinex Inc, Rochester, NY USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷
关键词：
D O I：
10.1136/jitc-2022-SITC2022.0645
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
645
引用
收藏
页码：A676 / A676
页数：1
相关论文
共 50 条
  • [41] Role of trastuzumab in the management of HER2-positive metastatic breast cancer
    Milani, Andrea
    Montemurro, Filippo
    Gioeni, Luisa
    Aglietta, Massimo
    Valabrega, Giorgio
    BREAST CANCER-TARGETS AND THERAPY, 2010, 2 : 93 - 109
  • [42] Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
    Murthy, R. K.
    Loi, S.
    Okines, A.
    Paplomata, E.
    Hamilton, E.
    Hurvitz, S. A.
    Lin, N. U.
    Borges, V.
    Abramson, V.
    Anders, C.
    Bedard, P. L.
    Oliveira, M.
    Jakobsen, E.
    Bachelot, T.
    Shachar, S. S.
    Mueller, V.
    Braga, S.
    Duhoux, F. P.
    Greil, R.
    Cameron, D.
    Carey, L. A.
    Curigliano, G.
    Gelmon, K.
    Hortobagyi, G.
    Krop, I.
    Loibl, S.
    Pegram, M.
    Slamon, D.
    Palanca-Wessels, M. C.
    Walker, L.
    Feng, W.
    Winer, E. P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (07): : 597 - 609
  • [43] TRASTUZUMAB EMTANSINE FOR THE TREATMENT OF HER2-POSITIVE METASTATIC BREAST CANCER
    Haddley, K.
    DRUGS OF TODAY, 2013, 49 (11) : 701 - 715
  • [44] Trastuzumab Deruxtecan in cerebral metastatic HER2-positive Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2025, 85 (04) : 354 - 354
  • [45] Trastuzumab beyond progression in HER2-positive metastatic breast cancer
    Al-Naqqash, Manwar
    Jasim Al-Serarati, Waleed
    Farooq Kareem, Tara
    BREAST JOURNAL, 2021, 27 (03): : 297 - 299
  • [46] Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients
    Yamshiro, Hiroyasu
    Iwata, Hiroji
    Masuda, Norikazu
    Yamamoto, Naohito
    Nishimura, Reiki
    Ohtani, Shoichiro
    Sato, Nobuki
    Takahashi, Masato
    Kamio, Takako
    Yamazaki, Kosuke
    Saito, Tsuyoshi
    Kato, Makoto
    Lee, Tecchuu
    Ohno, Shinji
    Kuroi, Katsumasa
    Takano, Toshimi
    Takada, Masahiro
    Yasuno, Shinji
    Morita, Satoshi
    Toi, Masakazu
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2015, 20 (04) : 709 - 722
  • [47] Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients
    Hiroyasu Yamshiro
    Hiroji Iwata
    Norikazu Masuda
    Naohito Yamamoto
    Reiki Nishimura
    Shoichiro Ohtani
    Nobuki Sato
    Masato Takahashi
    Takako Kamio
    Kosuke Yamazaki
    Tsuyoshi Saito
    Makoto Kato
    Tecchuu Lee
    Shinji Ohno
    Katsumasa Kuroi
    Toshimi Takano
    Masahiro Takada
    Shinji Yasuno
    Satoshi Morita
    Masakazu Toi
    International Journal of Clinical Oncology, 2015, 20 : 709 - 722
  • [48] Trastuzumab emtansine (T-DM1) + capecitabine in HER2-positive metastatic breast cancer (mBC) and HER2-positive locally advanced (LA)/metastatic gastric cancer (mGC): Results from the phase I/randomized phase II TRAXHER2 study
    Cortes, Javier
    Dieras, Veronique
    Lorenzen, Sylvie
    Montemurro, Filippo
    Riera-Knorrenschild, Jorge
    Thuss-Patience, Peter
    Allegrini, Giacomo
    De laurentiis, Michele
    Lichinitser, Mikhail
    Lohrisch, Caroline
    Perez-Garcia, Jose
    Ricci, Francesco
    Sakaeva, Dina
    Serpanchy, Rosanne
    Sufliarsky, Jozef
    Vidal, Maria
    Irahara, Natsumi
    Wohlfarth, Christine
    Aout, Mounir
    Gelmon, Karen
    CANCER RESEARCH, 2018, 78 (13)
  • [49] A phase I clinical trial of entinostat and lapatinib in patients with trastuzumab refractory HER2-positive metastatic breast cancer
    Willey, Jie
    Alvarez, Ricardo H.
    Booser, Daniel J.
    Giordano, Sharon H.
    Gonzalez-Angulo, Ana M.
    Murray, James L.
    Valero, Vincente
    Lee, Jangsoon
    Ueno, Naoto T.
    Jackson, Summer A.
    Faruqi, Fahad A.
    CANCER RESEARCH, 2015, 75
  • [50] Safety of trastuzumab deruxtecan and radiation therapy combination in HER2-positive metastatic breast cancer patients
    Visani, L.
    Ratosa, I.
    Ribnikar, D.
    Becherini, C.
    Bertini, N.
    Bonaparte, I.
    Stefanovski, D.
    Dobnikar, N.
    Desideri, I.
    Mattioli, C.
    Valzano, M.
    Banini, M.
    Salvestrini, V.
    Bernini, M.
    Tommasi, C.
    Nori, J.
    Orzalesi, L.
    Bianchi, S.
    Livi, L.
    Meattini, I.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 60 - 61
12345